Evotec SE (NASDAQ:EVO) stock is trading lower on Tuesday.
The drug discovery firm announced a new strategic transformation initiative called “Horizon,” aimed at reshaping its operating model, improving margins, and positioning the company for long-term growth in the drug discovery and preclinical development market.
The initiative builds on the company’s earlier “Priority Reset” and strategic roadmap introduced over the past two years.
“Horizon positions Evotec for stronger performance through 2027 and lays the foundation for further optimization and intelligent scaling toward 2030,” Christian Wojczewski, Evotec CEO, said.
Organizational Simplification And Workforce Changes At Evotec
As part of the transformation, Evotec will simplify its organizational structure and consolidate its global expertise into new Centers of Excellence designed to strengthen scientific collaboration and innovation.
The company also plans to reduce its global site footprint from 19 locations in 2024 to 10 sites over the next two years.
The restructuring is expected to affect up to 800 positions across various locations.
Implementation of Horizon has already begun, with initial operational effects anticipated in the second half of 2026.
The transformation is expected to be substantially completed by the end of 2027.
Evotec Financial Impact And Cost Savings
The initiative is projected to generate approximately 75 million euros (around $87.3 million) in annual run-rate cost savings by 2027.
To implement Horizon, Evotec expects restructuring-related cash charges of roughly 100 million euros between 2026 and 2028, along with potential non-cash impairment charges.
Updated Financial Outlook And 2025 Performance
Evotec also shared preliminary fiscal 2025 sales of about 788 million euros and adjusted EBITDA of roughly 41 million euros, both within its previously communicated guidance.
Looking ahead to 2026, the company expects revenue between 700 million and 780 million euros and adjusted EBITDA of 0 to 40 million euros, reflecting what executives described as a transition year during the restructuring process.
Over the longer term, Evotec expects revenues to exceed 1 billion euros between 2026 and 2030, with adjusted EBITDA margins projected to reach 20% by 2028 and surpass that level by the end of the decade.
EVO Price Action: Evotec shares were down 10.40% at $2.71 at the time of publication on Tuesday. The stock is trading at a new 52-week low, according to Benzinga Pro data.
Image via Shutterstock
Recent Comments